Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02080936

Acronym

M2W

Enrollment

138

Registered

2014-03-07

Start date

2014-01-31

Completion date

2014-03-31

Last updated

2014-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

Experimental approaches, Peripheral muscle Keyword, Rehabilitation

Brief summary

Peripheral muscle mass and strength are relevant indicators of COPD survival. Current guidelines recommend to assess muscle strength only in muscle wasted patients. However, a recent study reported quadriceps weakness without muscle wasting (Menon, M et al. Resp. Res.2012, 13:119). Thus, these guidelines raise the risk to miss out some weak patients. In clinical settings, fat-free-mass index (FFMI) is indicated as a simple index to assess muscle wasting. We aimed at determining the prevalence of patients entering in pulmonary rehabilitation (PR) a priori not eligible for muscle strength evaluation given the lack of muscle wasting clinical signs.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients who have got FFMI (bioimpedance) * Patients who have done quadriceps muscle strenght evaluation

Exclusion criteria

* Patients without FFMI * Patients without quadriceps muscle strenght

Design outcomes

Primary

Measure	Time frame
Muscle wasting in COPD patient	baseline

Secondary

Measure	Time frame
Muscle weakness in COPD patient	baseline

Countries

France

Outcome results